Situation: A 17-year-old boy comes alone to the social hygiene clinic of the Rural Health Unit (RHU). He has injected drugs with shared needles over the past year and asks to be tested for human immunodeficiency virus (HIV) and hepatitis C. He asks that his parents not be told about his visit. His hepatitis C antibody test is reactive, and a follow-up hepatitis C virus (HCV) RNA test shows no virus detected. How should the nurse interpret these results?

A reactive hepatitis C antibody shows exposure at some time, but only a positive HCV RNA confirms current infection. With RNA not detected, he has no current infection, most often because an earlier infection cleared. He still needs counseling on safe injection practices, because the antibody does not protect him from reinfection.

A reactive hepatitis C antibody test indicates that the body has produced antibodies against HCV at some point, but it does not by itself prove that the virus is currently present. The antibody can remain detectable for years after the infection has cleared, whether spontaneously or following treatment. Because antibody reactivity can represent anything from a resolved past infection to a false-positive screening result, confirmatory testing is required before any diagnosis of active hepatitis C is made ^[1][3].

In this adolescent, the follow-up HCV RNA test showed no virus detected. HCV RNA is the direct marker of viral replication, so a negative RNA result means there is no circulating virus and therefore no current infection. The combination of a reactive antibody and an undetectable HCV RNA is most consistent with past exposure to HCV that did not progress to chronic infection ^[1][2]. The immune system cleared the virus without treatment, which occurs in a meaningful proportion of acute HCV infections.

A reactive anti-HCV antibody reflects exposure, while only a positive HCV RNA confirms active infection. The antibody is not a neutralizing or protective antibody, so the patient remains susceptible to reinfection if he continues to share needles or engage in other parenteral exposures ^[3]. This is a critical counseling point for a 17-year-old who injects drugs.

The window period for hepatitis C must also be considered, but it does not explain this result. In early infection, HCV RNA becomes detectable within 1 to 2 weeks, while anti-HCV antibodies may take 6 to 12 weeks to appear. If this patient were in the window period of an early infection, the RNA would be positive and the antibody might still be negative or weakly reactive. The finding here is the opposite pattern: antibody reactive, RNA not detected. Therefore, early infection in the window period is not the correct interpretation ^[1][3].

There is no hepatitis C vaccine available for clinical use. Antibody positivity in this case cannot represent vaccine-induced immunity, because no HCV vaccine exists. The antibody detected is a marker of natural exposure, not immunization ^[3].

Test result pattern	Interpretation	Clinical meaning
Anti-HCV reactive, HCV RNA not detected	Past exposure, no current infection	Infection cleared spontaneously or after treatment; no active hepatitis C
Anti-HCV reactive, HCV RNA detected	Current HCV infection	Active viral replication; requires antiviral treatment evaluation
Anti-HCV nonreactive, HCV RNA detected	Very early acute infection	Window period before antibody seroconversion
Anti-HCV nonreactive, HCV RNA not detected	No evidence of HCV exposure	No current or past infection

Watch out! A reactive antibody test alone is not a diagnosis of hepatitis C. Confirmatory HCV RNA testing is essential, and missed RNA testing after a reactive antibody is a recognized gap in the diagnostic care cascade ^[2].

Key point! The antibody does not protect against reinfection. Even after spontaneous clearance, continued injection drug use with shared needles places this patient at risk for a new HCV infection, as well as HIV and other bloodborne pathogens.

In the clinical setting, the nurse should interpret these results as past exposure with no current infection. The priority is not antiviral treatment, because there is no active virus to treat. Instead, the focus shifts to risk-reduction counseling, harm reduction strategies such as access to sterile injection equipment, and follow-up testing for HIV and other infections given the shared needle exposure. The adolescent’s request for confidentiality must be handled according to local laws and RHU policies regarding minors and sensitive health services, while ensuring he receives appropriate education about transmission and reinfection risk ^[2][3].